• Vol. 44 No. 10, 406–414
  • 15 October 2015

Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC)



Download PDF


Introduction: The SCAN genitourinary cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy of metastatic renal cell carcinoma (mRCC).

Materials and Methods: The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting.

Results: : Six international guidelines were evaluated—those developed by the National Comprehensive Cancer Network (2014), the European Association for Urology (2013), the European Society of Medical Oncology (2012), the National Institute of Health and Clinical Excellence (2011), the Canadian Kidney Cancer Forum (2013) and the Asian Oncology Summit (2012). Recommendations on the first-, second- and third-line treatment for mRCC were developed.

Conclusion: These adapted guidelines form the SCAN Guidelines 2015 for systemic therapy of mRCC

Kidney cancer accounts for less than 1% of all cancers. There are over 200,000 new cases diagnosed with renal cell carcinoma (RCC) and over 100,000 deaths a year worldwide. It is slightly more common in men than in women, and is mainly detected in people in their middle age. In Singapore, kidney cancer (together with other urothelial cancers) ranks as the 9th most common cancer in males.

This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.